---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-223590"
form_type: "8-K"
ticker: "INTI"
cik: "0001042418"
company_name: "Inhibitor Therapeutics, Inc."
filed_at: "2023-08-29T23:59:59+00:00"
generated_at: "2026-06-11T02:13:03.973997+00:00"
event_type: "other"
sentiment: "neutral"
materiality_score: 0.4
calibrated_materiality_score: 0.4
confidence: "high"
source: SEC EDGAR
---

# Inhibitor Therapeutics expands board to 7, appoints Ronald Osman; bylaws amended

## Summary
- Board increased from 4 to 7 members; Ronald E. Osman appointed as non-independent director.
- Amended bylaws require stockholders holding 50% of outstanding shares to bring business at annual meetings.
- Bylaw amendment raises vote threshold to amend/repeal bylaws from majority to 66 2/3% of voting stockholders.
- Expanded CFO and Secretary roles; removed references to Amended and Restated Equity Holders Agreement.
- Mr. Osman is a licensed attorney with over 40 years of experience in False Claims Act litigation.

## SEC filing metadata
- accession: 0001193125-23-223590
- form_type: 8-K
- ticker: INTI
- cik: 0001042418
- company_name: Inhibitor Therapeutics, Inc.
- filed_at: 2023-08-29T23:59:59+00:00
- event_type: other
- sentiment: neutral
- materiality_score: 0.4
- calibrated_materiality_score: 0.4
- confidence: high
- sec_items: 5.02, 5.03, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1042418/000119312523223590/0001193125-23-223590-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1042418/000119312523223590/d878120d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-223590
- JSON: https://secwatch.observer/filing/0001193125-23-223590.json
- Plain text: https://secwatch.observer/filing/0001193125-23-223590.txt

## Key facts
- Executive change
  Ronald E. Osman was appointed as Director at Inhibitor Therapeutics, Inc..
  - Action: appointed
  - Role: Director
  source text: On August 23, 2023, the Board of Directors (the “ Board ”) of Inhibitor Therapeutics, Inc. (the “ Company ”) increased the number of directors on the Board from four (4) members to seven (7) members and appointed Ronald E. Osman to fill one of the vacancies of the Board.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1042418/000119312523223590/0001193125-23-223590-index.htm
- Governance Changes
  Inhibitor Therapeutics, Inc.: The Board amended the Bylaws to increase the stockholder vote threshold for bringing business at annual meetings, expand CFO and Secretary roles, provide indemnification reimbursement, raise the amendment/repeal/removal vote threshold to 66 2/3%, and remove references to the Equity Holders Agreement (effective 2023-07-12).
  - Change: bylaw amendment
  - Effective: 2023-07-12
  source text: On July 12, 2023, the Board amended the Bylaws (the “ Amended and Restated Bylaws ”) to, among other things: (i) provide that stockholders holding an aggregate of at least 50% of the entire capital stock issued and outstanding and entitled to vote at the meeting are required in order to bring business to be conducted at an annual meeting; (ii) expand the roles and duties of a Chief Financial Officer and a Secretary of the Company; (iii) to provide for the reimbursement of indemnified individuals in accordance with the laws of Delaware; (iv) increased the threshold of stockholder votes required for the amendment, repeal, or removal of the Amended and Restated Bylaws from a majority of the stockholders entitled to vote at such meeting to sixty-six and two-thirds percent (66 2/3%) of the stockholders entitled to vote at such meeting, and (v) remove all references and requirements related to the Amended and Restated Equity Holders Agreement by and among the Corporation, Mayne Pharma Ventur
  evidence_url: https://www.sec.gov/Archives/edgar/data/1042418/000119312523223590/0001193125-23-223590-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.